Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
CNS Spectrums|January 17, 2025
Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trialRoger S McIntyre, Gregory Mattingly, Yordan Godinov, et al.
The Journal of Clinical Psychiatry|January 7, 2015
Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorderDong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.
Journal of Clinical Psychopharmacology|August 19, 2021
Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or BehaviorCarla M Canuso, Dawn F Ionescu, Xiang Li, et al.
BMJ Open|April 18, 2023
Feasibility study to evaluate capabilities for conducting psychiatric clinical research within the Rwandan mental healthcare systemLarry Alphs, Ibrahim Turkoz, Virginia Smith-Swintosky, et al.
The Journal of Clinical Psychiatry|September 27, 2023
Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc AnalysisOliver J Lopena, Larry D Alphs, Martha Sajatovic, et al.
Schizophrenia Bulletin|February 9, 2018
Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia DiagnosesAriana E Anderson, Stephen Marder, Steven P Reise, et al.
The Journal of Clinical Psychiatry|July 21, 2021
Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM StudiesIbrahim Turkoz, Ella Daly, Jaskaran Singh, et al.
Depression and Anxiety|July 22, 2021
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorderElla J Daly, Ibrahim Turkoz, Giacomo Salvadore, et al.
Psychiatry Research|April 5, 2023
Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal sprayIbrahim Turkoz, J Craig Nelson, Samuel T Wilkinson, et al.
CNS Drugs|August 9, 2023
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 StudyMeredith Castro, Samuel T Wilkinson, Rayan K Al Jurdi, et al.
Pageof 10